5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure

Joint Authors

Kojonazarov, Baktybek
Janssen, Wiebke
Schymura, Yves
Novoyatleva, Tatyana
Boehm, Mario
Wietelmann, Astrid
Luitel, Himal
Murmann, Kirsten
Krompiec, Damian Richard
Tretyn, Aleksandra
Pullamsetti, Soni Savai
Ghofrani, Hossein Ardeschir
Schermuly, Ralph Theo
Weissmann, Norbert
Seeger, Werner

Source

BioMed Research International

Issue

Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-8, 8 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2015-02-01

Country of Publication

Egypt

No. of Pages

8

Main Subjects

Medicine

Abstract EN

Objective.

The serotonin (5-HT) pathway was shown to play a role in pulmonary hypertension (PH), but its functions in right ventricular failure (RVF) remain poorly understood.

The aim of the current study was to investigate the effects of Terguride (5-HT2A and 2B receptor antagonist) or SB204741 (5-HT2B receptor antagonist) on right heart function and structure upon pulmonary artery banding (PAB) in mice.

Methods.

Seven days after PAB, mice were treated for 14 days with Terguride (0.2 mg/kg bid) or SB204741 (5 mg/kg day).

Right heart function and remodeling were assessed by right heart catheterization, magnetic resonance imaging (MRI), and histomorphometric methods.

Total secreted collagen content was determined in mouse cardiac fibroblasts isolated from RV tissues.

Results.

Chronic treatment with Terguride or SB204741 reduced right ventricular fibrosis and showed improved heart function in mice after PAB.

Moreover, 5-HT2B receptor antagonists diminished TGF-beta1 induced collagen synthesis of RV cardiac fibroblasts in vitro.

Conclusion.

5-HT2B receptor antagonists reduce collagen deposition, thereby inhibiting right ventricular fibrosis.

Chronic treatment prevented the development and progression of pressure overload-induced RVF in mice.

Thus, 5-HT2B receptor antagonists represent a valuable novel therapeutic approach for RVF.

American Psychological Association (APA)

Janssen, Wiebke& Schymura, Yves& Novoyatleva, Tatyana& Kojonazarov, Baktybek& Boehm, Mario& Wietelmann, Astrid…[et al.]. 2015. 5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. BioMed Research International،Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1055496

Modern Language Association (MLA)

Janssen, Wiebke…[et al.]. 5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. BioMed Research International No. 2015 (2015), pp.1-8.
https://search.emarefa.net/detail/BIM-1055496

American Medical Association (AMA)

Janssen, Wiebke& Schymura, Yves& Novoyatleva, Tatyana& Kojonazarov, Baktybek& Boehm, Mario& Wietelmann, Astrid…[et al.]. 5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1055496

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-1055496